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Abstract
Olanzapine (Olz) is one of the most effective antipsychotic drugs commonly used for treating schizophrenia. Unfortunately,
Olz administration is associated with severe weight gain and metabolic disturbances. Both patients and clinicians are highly
interested in the development of new antipsychotics which are as effective as atypical antipsychotics but which have a
lower propensity to induce metabolic side effects. In the present study, we examined two new derivatives of Olz; OlzEt (2-
ethyl-4-(49-methylpiperazin-19-yl)-10Hbenzo[b]thieno[2,3-e][1,4]diazepine), and OlzHomo (2-ethyl-4-(49-methyl-19,49-diaze-
pan-19-yl)-10H-benzo[b]thieno[2,3-e] [1,4]diazepine), for their tendency to induce weight gain in rats. Weight gain and
metabolic changes were measured in female Sprague Dawley rats. Animals were treated orally with Olz, OlzEt, OlzHomo (3
or 6 mg/kg/day), or vehicle (n = 8), three times daily at eight-hour intervals for 5 weeks. Furthermore, a phencyclidine (PCP)-
treated rat model was used to examine the prevention of PCP-induced hyperlocomotor activity relevant for schizophrenia
therapy. Male Sprague Dawley rats were pre-treated with a single dose (3 mg/kg/day) of Olz, OlzEt, OlzHomo, or vehicle
(n = 12), for 2 weeks. Locomotor activity was recorded following a subcutaneous injection with either saline or PCP (10 mg/
kg). Olz was found to induce weight gain, hyperphagia, visceral fat accumulation, and metabolic changes associated with
reduced histamatergic H1 receptor density in the hypothalamus of treated rats. In contrast, OlzEt and OlzHomo presented
promising antipsychotic effects, which did not induce weight gain or fat deposition in the treated animals. Behavioural
analysis showed OlzEt to attenuate PCP-induced hyperactivity to a level similar to that of Olz; however, OlzHomo showed a
lower propensity to inhibit these stereotyped behaviours. Our data suggest that the therapeutic effectiveness of OlzHomo
may be delivered at a higher dose than that of Olz and OlzEt. Overall, OlzEt and OlzHomo may offer a better
pharmacological profile than Olz for treating patients with schizophrenia. Clinical trials are needed to test this hypothesis.
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Introduction
Olanzapine (Olz) is an effective atypical antipsychotic drug used
for treating severe psychiatric disorders, including schizophrenia
and bipolar disorder [1,2]. However, Olz administration is
associated with excessive weight gain and severe metabolic side
effects such as type II diabetes mellitus, hyperglycemia, dyslipide-
mia, and insulin resistance [1,3,4,5,6]. A novel antipsychotic drug
that retains the clinical efficacy of Olz but causes less treatment-
emergent weight gain would be an invaluable breakthrough in
schizophrenia therapy. For the last few years, researchers have
focused on developing novel antipsychotics with fewer metabolic
side effects [7]. Nonetheless, the crucial need for developing an
ideal antipsychotic agent for schizophrenia still continues. It is
suggested that the simultaneous blockade of the dopamine D2 and
serotonin 5HT2A receptors with Olz through the various
dopaminergic pathways is involved in the molecular mechanisms
of Olz’s therapeutic efficacy, resulting in the distinct clinical
properties of this drug [8,9,10,11]. Changes in hormonal peptide
levels correlated with food intake (such as insulin and leptin) have
been suggested to play a part in the weight gain induced by
atypical antipsychotic drug treatments [12]. Olz in particular
significantly influences the regulation of plasmatic insulin and
leptin, although the mechanism of action remains elusive [13,14].
A large number of studies have also reported a relevant role for the
affinities of atypical antipsychotics for the serotonergic 5HT2A,
5HT6, and 5HT7 receptors; adrenergic a1A receptor; and
particularly histamatergic H1 and serotonergic 5HT2C receptors
in their obesogenic effects [2,15,16,17].
The blockade of the H1 receptors has been repeatedly described
as the most likely mechanism for atypical antipsychotic drug-
induced weight gain [18,19,20]. The inhibition of the H1 receptors
is directly involved in the activation of hypothalamic AMPK (59
adenosine monophosphate-activated protein kinase) signalling,
which stimulates food intake and positive energy balance and
reverses the anorexigenic effects of leptin [18]. A strong link
between H1 receptor affinity with antipsychotic agents and weight
gain susceptibility has been reported [21]. Clozapine and Olz,
which have a higher affinity for the H1 receptors (Ki = 1.2 nM and
Ki = 2.0 nM, respectively), showed a greater propensity to induce
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weight gain [15,22]. However, antipsychotic drugs with a lower
H1 receptor antagonist affinity, such as loxapine and amoxapine,
caused neither weight gain nor weight loss in patients treated with
these medications [23,24]. Thus, the development of a novel
antipsychotic agent with a similar 5HT2A/D2 receptor binding
affinity ratio to that of Olz [25,26], and with a lower affinity for the
H1 receptors, may significantly advance schizophrenia therapy.
We have previously examined two new analogues of Olz; OlzEt
(2-ethyl-4-(49-methylpiperazin-19-yl)-10Hbenzo[b]thieno[2,3-e][1,4]
diazepine) [68], and OlzHomo (2-ethyl-4-(49-methyl-19,49-diaze-
pan-19-yl)-10H-benzo[b]thieno[2,3-e] [1,4]diazepine) (newly synthe-
sised by our research group) [27], presenting an ethyl substituent at
position 2 of the thiophene ring of Olz compounds. We have
demonstrated in our previous published study [27] that both of these
analogues showed an in vitro lower affinity for the H1 receptors while
maintaining similar affinities for the D2 and 5HT2A receptors when
compared to Olz. Since the blockade of the H1 receptors has been
repeatedly described as the most likely mechanism for atypical
antipsychotic drug-induced weight gain, the present study further
explored the therapeutic potential in vivo of these two analogues of
Olz in an animal model of schizophrenia while assessing their
metabolic side effects. We found that OlzEt and OlzHomo
compounds display a significant reduction in metabolic side effects
(weight gain and adiposity) compared to Olz. Thus OlzEt and
OlzHomo may present as potential new drugs for schizophrenia
therapy.
Materials and Methods
Ethics statement
All experimental procedures were approved by the Animal
Ethics Committee, University of Wollongong, and conducted in
accordance with the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes (2004).
Study (1) Animals and drug treatment regimes. In the
first series of experiments (Study 1), female Sprague Dawley rats (7
weeks old) were used to investigate weight gain and adiposity
effects of a chronic treatment with Olz, OlzEt, and OlzHomo.
Animals were obtained from the Animal Resources Centre (Perth,
WA, Australia) and housed individually at 22uC, on a 12 h light-
dark cycle with ad libitum access to water and standard laboratory
chow diet (3.9 kcal/g, 74% carbohydrate, 16% protein, and10%
fat). Animals were then randomly assigned to one of the following
treatment groups: 3 or 6 mg/kg/day of Olz (Bosche Scientific, NJ,
USA), OlzEt (Lichem, Hebei Boyuan Co., China), OlzHomo
(Lichem, Hebei Boyuan Co., China), or vehicle (n = 8), three times
daily at eight-hour intervals. Following 1 week habituation in their
new environment, the animals underwent training to self-
administer a sweet cookie dough pellet for 1 week. Cookie dough
(62% carbohydrate, 22% protein, 10% vitamins, 6% fiber, and
minerals) administration was performed as previously reported for
5 weeks [33]. Over the course of this experiment, animals were
weighed twice per week. Food and water consumption were also
monitored every 48 hours for each animal and results were
corrected for spillage.
Post-mortem hormone, lipid and tissue analysis. At the
end of Study 1, female rats were fasted for 10 h prior to sacrifice
by carbon dioxide asphyxiation. Upon sedation, blood was
removed and collected in Lavender Vacutainer tubes containing
EDTA (ethylenediaminetetraacetic acid; 5-HT, 5-hydroxytrypta-
mine (serotonin) for hormonal testing. Samples were immediately
centrifuged (1000 g for 10 min at 4uC), after which plasma was
aliquoted and stored at 220uC until use. Fasting plasma insulin,
leptin, and adiponectin levels were measured using commercially
available Milliplex kits (Millipore Corp., USA) and Luminex 100.
Plasma samples were processed by Southern IML Pathology for
levels of glucose, cholesterol, triglycerides, high-density lipoprotein
(HDL), and low-density lipoprotein (LDL) levels. White fat pads
and sub-scapula brown fat pads were dissected from each animal
and individually weighed. Brains were immediately removed,
dissected into hypothalamus and prefrontal cortex, snap frozen in
liquid nitrogen and then stored at -80uC until use.
Study (2) Animals and drug treatment regimes. In the
next experiment (Study 2), the effects of Olz, OlzEt, and
OlzHomo subchronic administration on PCP-induced behaviours
were tested in male Sprague Dawley rats (180–200 g). Animals
were housed in pairs in the same conditions described above.
Following a 1 week habituation period, rats were treated orally
with a sweet cookie dough pellet containing 3 mg/kg/day of Olz,
OlzEt, OlzHomo, or vehicle (n = 12), three times daily at eight-
hour intervals for 2 weeks. Animals were injected subcutaneously
with either saline or PCP (10 mg/kg, synthesized in the School of
Chemistry, University of Wollongong, Wollongong, New South
Wales, Australia) 30 min following the final drug/cookie admin-
istration. Open-field behavioural testing was performed 15 min
after this injection.
Behavioural analysis and post mortem
measurement. The open field test was used to determine the
behavioural effects of the pre-treatment of Olz, OlzEt, and
OlzHomo on PCP-treated animals. To minimise stress during the
experiment, animals underwent a 10 min habituation period for
the open-field test one day prior to the experiment. As previously
described [65], the locomotor activity was recorded for each tested
animal in a black open square box (60 cm660 cm640 cm).
Behavioural parameters including the total distance travelled (cm),
mean velocity (cm/s), central and peripheral duration (s), and
frequency of rearing were measured for 30 min and then analysed
via Ethovision video-tracking software (Nodulus Information
Technology, Wageningen, The Netherlands). Animals were
euthanized 120 min following the open-field test as described
above; brains were rapidly removed from the skull and dissected
into prefrontal cortex and striatum, snap frozen in liquid nitrogen
and stored at 280uC until required for the receptor binding
assays.
Radioligand binding assays. The striatum, prefrontal
cortex, and hypothalamus were used in radioligand binding assays
to measure the receptor binding density of D2, 5HT2A, and H1
receptors respectively. The assays were performed according to
previously described procedures [66,67]. In brief, the striatum,
prefrontal cortex, and hypothalamus were homogenized separately
and then centrifuged (27,000 g for 15 min at 4uC). The resultant
membrane was incubated in the presence of 2 nM [3H]-Spiperone
(specific activity, 15 Ci/mmol, 1mCi/ml; Perkin Elmer, Australia),
with or without 2 mM (+) butaclamol (Sigma, Australia), 10 nM
[3H]-Ketanserine (specific activity, 67 Ci/mmol, 1mCi/ml; Perkin
Elmer, Australia) in the absence or presence of 10 mM
methysergid (Sigma, Australia), or Pyrilamine (specific activity,
37 Ci/mmol, 1mCi/ml; Perkin Elmer, Australia) with or without
2 mM doxepin (Sigma, Australia), for D2, 5HT2A, and H1 receptor
binding assays, respectively. Radioactivity was measured by a beta
liquid scintillation analyser (Perkin Elmer, Tri-Crab 2800 TR).
Data analysis. Data were statistically analysed using SPSS
(version 17.0 SPSS, Chicago, IL, USA). Total weight gain, total
food intake, energy efficiency, insulin, leptin, adiponectin, glucose,
cholesterol, triglycerides, HDL, LDL, fat mass, and binding
density were analysed by one-way analyses of variance (ANOVA)
for each dose of Olz, OlzEt, and OlzHomo. Repeated ANOVA
measures (COMPOUNDS6DAYS as repeated measures) were
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employed for cumulative weight gain, and food and water intake.
Open-field parameters were also analysed by one-way ANOVA.
Student’s t-tests were used to determine the significance of
differences between the saline and PCP-treated rats. Multiple
comparisons were performed using Tukey or Games–Howell post
hoc tests. Where Kolmogorov–Smirnov tests showed data to be
distributed non-parametrically, Kruskall–Wallis tests were applied
followed by Mann–Whittney U post hoc analysis. Correlations
were identified using Pearson’s correlation tests or Spearman’s
correlation tests for non-parametric data. Linear regression was
performed in groups with significant correlations. Significance was
set at P,0.05.
Results
Study (1) Weight gain and metabolic side effects of Olz,
OlzEt, and OlzHomo
Body weight gain, food and water intake. Body weight
gain was found to be significantly increased following both 3 mg/
kg (F3,27 = 7.11, P= 0.001) and 6 mg/kg (F3,27 = 23.27, P,0.001)
Olz administration compared to the control group. However, the
effects of both OlzEt and OlzHomo on body weight gain were not
significantly altered compared to the control groups. OlzEt and
OlzHomo showed a significant reduction in weight gain compared
to the Olz group with 3 mg/kg (226%, P,0.05 for both
compounds) and 6 mg/kg doses (232% and 248%, P,0.001,
respectively) (Figure 1). A repeated ANOVA measure (treatment6
days) revealed a significant effect of time on the progressive
enhancement of body weight for both doses of Olz (3 mg/kg and
6 mg/kg) (F3.37,90.90 = 246.06, P,0.001, and F3.32,92.89 = 289.38,
P,0.001, respectively), and the interaction between these two
factors (F10.10,90.90 = 2.34, P,0.05, and F9.95,92.89 = 5.53,
P,0.001, respectively). As illustrated in Figure 2, administration
of Olz (at both tested doses) gradually increased weight gain from
day 4 to the end of the treatment period. In contrast, the effect of
OlzEt and OlzHomo on cumulative body weight was not
significant compared to controls (Figure 2). Higher doses of Olz
treatment (6 mg/kg) induced a significant increase in food intake
(F3,27 = 10.73, P= 0.001) that began after 6 days of treatment. In
contrast, OlzEt and OlzHomo administration did not affect food
intake for either of the tested doses. Post hoc analysis showed that
total food intake after 5 weeks of treatment with OlzEt and
OlzHomo (6 mg/kg) was significantly lower than Olz administra-
tion (14% and P= 0.001, 29% and P=0.006, respectively)
(Figure 2)). A significant positive correlation between total body
weight gain and total food intake was found after 5 weeks of
treatment (r = 0.48, P,0.001) (Table S1).
Fat deposition. Visceral fat deposition (intra-abdominal,
including retroperitoneal) was significantly increased in 6 mg/kg
Olz treated rats compared to the control group (F3,28 = 8.98,
P=0.002). However, OlzEt and OlzHomo treated animals (3 mg/
kg and 6 mg/kg, P.0.05) did not show any significant difference
in relation to visceral fat deposition compared to controls (Table 1).
Significant positive correlations were found between body weight
gain and food intake with fat mass (r=0.42, P=0.002 and r=0.59,
P,0.001, respectively) (Table S1). There were no effects of
treatments on sub-scapula brown fat mass compared to the control
group (Table 1).
Plasma hormone and glucose levels. Olz treatment at a
dose of 6 mg/kg caused a significant reduction in fasting plasma
insulin levels in the tested animals compared to the control rats
(F3,23 = 10.46, P,0.01). In contrast, OlzEt and OlzHomo
administration did not affect the fasting plasma insulin levels in
the tested rats compared to the controls. Additionally, both
compounds showed higher insulin levels than those measured in
Olz treated animals with 6 mg/kg doses (48%, P=0.001, and
54%, P=0.013, respectively) (Figure 3). The insulin levels were
not significantly altered in the treated groups (Olz, OlzEt, and
OlzHomo) for the 3 mg/kg dose compared to the control animals.
Post hoc analysis did not show any significant difference in the
leptin levels of animals treated with Olz at both 6 mg/kg
(F3,22 = 6.92, P=0.95) and 3 mg/kg (F3,21 = 5.33, P= 1.00) doses
compared to the control groups. However, plasma leptin levels
were significantly decreased following both 3 mg/kg and 6 mg/kg
OlzHomo (P= 0.01 and P,0.01, respectively) compared to
controls. Fasting plasma adiponectin levels were found to be
significantly higher after chronic administration of Olz (at the
3 mg/kg and 6 mg/kg doses, F3,23 = 22.45, P,0.01, and
F3,24 = 18.28, P,0.001, respectively) but were found to be lower
following OlzHomo treatment (at the 3 mg/kg dose, P=0.039)
compared to controls (Figure 3). Both leptin and adiponectin levels
for the animals treated with OlzEt were not significantly altered at
both tested doses compared to controls) (Figure 3). A significant
negative correlation was found between plasma insulin levels and
food intake (r=20.46, P=0.002), as well as a significant positive
correlation between leptin levels and fat deposition (r=0.34,
P=0.026) (Table S1). Plasma glucose levels were found to be not
significantly altered following treatment with Olz, OlzEt or
OlzHomo at either the 3 mg/kg dose or the 6 mg/kg dose
compared to the control rats (Figure 3).
Plasma lipid levels. Levels of plasma cholesterol, triglycer-
ides and LDL were found to be unaltered in the treatment groups
(Olz, OlzEt, OlzHomo) at both the 3 mg/kg and the 6 mg/kg
dose compared to controls (Table 4). HDL levels were found to be
significantly decreased in both the OlzEt 6 mg/kg treated animals
and in the OlzHomo 3 mg/kg treated animals compared to
controls (P = 0.027 and P=0.007 respectively) (Table 4). However
there was no significant difference in HDL levels in any of the
other treatment groups at either dose (Table 4).
Aterations in H1 receptor density. Olz (3 mg/kg and
6 mg/kg) significantly reduced the H1 receptor density in the
hypothalamus of the female animals treated for 5 weeks
(F3,12 = 4.01, P,0.05, and F3,12 = 23.06, P,0.001, respectively)
compared to controls, while the H1 receptor density remained
unchanged in animals treated with either OlzEt or OlzHomo for
both tested doses (Table 2). There was a significant negative
correlation between total body weight gain and visceral fat mass
with H1 receptor density in the hypothalamus (r =20.59,
P= 0.001, and r =20.61, P= 0.001, respectively) (Table S1).
Study (2) Behavioural and neurochemical study: A
comparison between Olz, OlzEt, and OlzHomo
treatments
Behavioural testing. Behavioural results are illustrated in
Table 3. In the saline groups, no significant difference was found
following 2 weeks of treatment with Olz, OlzEt, or OlzHomo in all
the parameters measured in the open-field test. However, in
animals acutely administered with PCP, total distance moved,
mean velocity, and centre and periphery durations differed
significantly according to the tested treatments (Olz, OlzEt, and
OlzHomo). No sedative behaviour was observed in PCP-treated
rats. Total distance moved was significantly reduced in Olz and
OlzEt (F3,31 = 4.97, P = 0.023, and F3,31 = 8.19, P= 0.008) treated
rats compared to controls. However, the effect of OlzHomo
treatment on reducing locomotor activity was not significant
compared to the controls (P = 0.42). Mean velocity was also
reduced in animals treated with Olz (F3,44 = 8.22 and P,0.05).
One-way ANOVA revealed significant changes in the centre and
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periphery durations following 2 weeks of treatment with OlzEt
(F3,33 = 4.37, P,0.01, and F3,41 = 3.21, P = 0.017, respectively).
Moreover, t-test results showed a significant effect of acute PCP
administration on the distance travelled in animals treated with
Olz, OlzEt, OlzHomo or control compared to their equivalent
saline groups.
Alteration in D2 and 5HT2A receptor densities. In the
saline groups, 2 weeks of treatment with Olz and OlzHomo
induced a significant reduction in D2 receptor density in the
striatum of the male rats compared to controls (F3,20 = 34.83,
P,0.001, and F3,20 = 31.25, P,0.001, respectively). However, in
the PCP-treated groups, a significant reduction was found
following Olz and OlzEt treatments (F3,20 = 40.75, P= 0.005)
compared to controls. Similarly, 5HT2A receptor density in the
prefrontal cortex of the animals treated with Olz and OlzEt was
significantly decreased in both saline (F3,20 = 125.03, P,0.001,
and F3,20 = 125.03P= 0.002, respectively) and PCP (F3,20 = 92.13,
P,0.001) groups (Table 2).
Discussion
Pharmacological and behavioural evidence of effective
analogues of Olz in an animal model: possible
applications in the clinic
N-methyl-D-aspartate (NMDA) receptor antagonist animal
models of schizophrenia such as PCP have been widely used to
test new drugs that have been developed for future schizophrenia
therapies [53]. These models offer reasonable validity with respect
to the clinical symptoms of schizophrenia, and to some degree
predict the efficacy of drugs in patients. In our study, we used the
PCP rat model to determine whether sub-chronic pre-treatment
with Olz, OlzEt, or OlzHomo could attenuate the characteristic
PCP-induced behaviours in adult male rats. We chose to focus this
study specifically in male rats since the effects of PCP injections
have been shown to be more pronounced in male compared to
female rats in several behavioural tests [69,70]. Coinciding with
previous reports [54,55,56], our results showed that PCP-treated
rats showed a remarkable increase in spontaneous locomotor
activity (i.e. total distance travelled or travel velocity) and anxiety/
exploratory related parameters (duration/frequency in centre or
periphery) of the open-field test compared to the saline group. It
has been suggested that the behavioural effects of PCP treatment
Figure 1. Total weight gain and food intake in female rats treated with Olz and Olz derivatives. A. Total body weight gain (g), B. Total
food intake (g) in female Sprague Dawley rats treated with Olz, OlzEt, OlzHomo (3 mg/kg or 6 mg/kg), or vehicle (Control) for 5 weeks. The data
points are the mean 6 SEM, **P,0.01 and ***P,0.001 vs. Control.
doi:10.1371/journal.pone.0080979.g001
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are due to the multiple mechanisms of action that may include
altered dopamine, serotonin and noradrenaline transmission
[53,57,58]. For instance, a disruption to the firing pattern of
dopaminergic neurons, which increases dopamine release in the
frontal cortex and activates the mesolimbic dopaminergic neurons,
may play a part in the PCP-induced psychotic behaviour which is
similar to that seen in schizophrenia patients. Altered activity of
glutamatergic neurons in the cortex, leading to elevated glutamate
release and a reduced inhibitory feedback onto the principal
neurons, is also involved in this mechanism [53].
Regarding its clinical relevance, Olz has been shown to
attenuate the hyperlocomotion and anxiety induced by PCP
administration in animals [59]. In our study, the observed PCP-
induced behaviours were largely blocked in the Olz and OlzEt
treatments in rats. Pre-treatment with Olz and OlzEt significantly
inhibited the hyperlocomotion induced by PCP in male rats.
Interestingly, OlzEt was more effective than the Olz treatment in
suppressing the anxiety-like behaviours of PCP, such as longer
time spent in the outer field and lower entries into the centre field,
suggesting the potential antipsychotic capacity of OlzEt. In
contrast, OlzHomo did not suppress the PCP-induced behaviours
measured in the open-field test. It is suggested that the mixed
antagonistic activity of Olz at multiple receptors, including
dopamine D1–D4; serotonin 5HT2A and 5HT2C; muscarinic M1;
and adrenergic a1, and a2 receptors, may underlie its ability to
block PCP-induced behaviours [53,60]. For instance, an increased
level of serotonin at synapses containing 5HT2A receptors plays a
part in PCP-induced hyperlocomotion. This effect may be
prevented by 5HT2A antagonism by Olz at the level of motor
pathways in the spinal cord or in the brain [61]. In our previous
study [27], OlzEt showed a similar affinity as Olz for blocking the
D2 and 5HT2A receptors in the striatum and prefrontal cortex
respectively, which may partly explain the way in which OlzEt
inhibits the PCP-induced behaviours in vivo. On the other hand,
Figure 2. Cumulative weight gain and food intake in female rats treated with Olz and Olz derivatives. A. Cumulative body weight gain
(g), B. Cumulative food intake (g) in female Sprague Dawley rats treated with Olz, OlzEt, OlzHomo (3 mg/kg or 6 mg/kg), or vehicle (Control) for 5
weeks. The data points are the mean 6 SEM. A. *P,0.05, **P,0.01: Olz 3 mg/kg vs. control. ##P,0.01, ###P,0.001: Olz 6 mg/kg vs. Control. B.
**P,0.01, ***P,0.001: Olz 6 mg/kg vs. Control. (*: Control, D: Olz 3 mg/kg, m: 6 mg/kg, e: OlzEt 3 mg/kg,¤: OlzEt 6 mg/kg, o: OlzHomo 3 mg/kg
and N: OlzHomo 6 mg/kg).
doi:10.1371/journal.pone.0080979.g002
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OlzHomo demonstrated a lower affinity for blocking these two
receptors, which may contribute to its lack of efficacy for
alleviating the PCP-induced hyperactivity. In fact, since the
ambulation in OlzHomo/PCP-treated rats was comparable to the
control/PCP group, we postulate that the potential for therapeutic
effectiveness of an OlzHomo regime may be achieved at a higher
dose than that at which Olz and OlzEt are administered.
To further validate our hypothesis regarding the effect of PCP
on the levels of D2 and 5HT2A receptors, we measured the
neurochemical changes in the brain following the PCP challenge.
Consistent with previous reports [51,62,63], our findings showed
Table 1. Body weight and fat pad mass in female rats treated with Olz and Olz derivatives.
Control Olz OlzEt OlzHomo
3 mg 6 mg 3 mg 6 mg 3 mg 6 mg
Body Weight (g)
IBW 226.43610.74 225.38610.04 225.1868.79 228.0968.46 224.6869.57 226.0069.8 223.6169.5
FBW 252.46611.01 281.08612.14 290.38±7.16* 266.7569.8 265.40610.00 265.03867.7 253.7610.00
Fat pad mass (g)
Total White fat 6.3160.93 8.0161.01 12.18±1.14*** 6.3260.73 8.5761.12 6.0161.06 5.1760.91
Subscapula (BAT) 0.3260.04 0.3060.04 0.2760.3 0.2760.2 0.2460.2 0.2760.02 0.2560.2
Total white fat/FBW (%; g/g) 2.3660.29 2.8560.28 4.28±0.31*** 2.3260.19 3.1660.30 2.2260.35 1.9660.27
Mean body weight and fat pad mass in female Sprague Dawley rats following 5 weeks treatment with Olz, OlzEt, OlzHomo (3 mg/kg or 6 mg/kg), or vehicle (Control).
IBW: initial body weight, FBW: final body weight. Data are expressed as mean 6 SEM,
*P,0.05, and.
***P,0.001 vs. Control.
doi:10.1371/journal.pone.0080979.t001
Figure 3. Hormonal profiles in female rats treated with Olz and Olz derivatives. A. Plasma Leptin (PM), B. Plasma Adiponectin (pg/ml), C.
Plasma insulin (PM), D. Plasma Glucose (mmol/L) in female Sprague Dawley rats treated with Olz, OlzEt, OlzHomo (3 mg/kg or 6 mg/kg), or vehicle
(Control) for 5 weeks. The data points are the mean 6 SEM, *P,0.05 and **P,0.01 vs. Control.
doi:10.1371/journal.pone.0080979.g003
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that the D2 and 5HT2A receptor densities in the striatum and
prefrontal cortex respectively, in adult male PCP-treated rats, did
not differ from saline-treated controls. However, subchronic
treatment with Olz and OlzEt induced a long-lasting down-
regulation in the binding capacities of D2 and 5HT2A receptors in
both saline and PCP-treated animals. As previously suggested, the
down-regulation of these two receptors may partly contribute to
the blockade of PCP-induced behavioural changes, including
hyperlocomotion [61,64]. However, this hypothesis should be
taken with a degree of caution, since altered dopamine and
serotonin receptor densities are not the only mechanisms
underlying the behavioural changes induced by PCP administra-
tion [53]. The extent to which such changes are involved in the
therapeutic effects of Olz and OlzEt remains to be investigated.
However, based on the pharmacological and behavioural results
reported in our study, OlzEt warrants further examination for the
treatment of schizophrenia.
Table 2. Brain receptor densities in female rats treated with Olz and Olz derivatives.
Receptor Control Olz OlzEt OlzHomo
3 mg 6 mg 3 mg 6 mg 3 mg 6 mg
H1 365.2615.9 289.7±4.6* 209.2±14.9*** 344.2626.9 367.2622.4 351.269.5 36067.7
D2
Saline 2009.2627.9 1677±23.6*** 1938.2618.6 1826±26.9***
PCP 2031.8642.9 1403.2±68.6** 1651.7±41.2** 2088.5645.9
5HT2A
Saline 73916264.8 2919±76.3*** 5528±117.9** 6604.26178.2
PCP 8835.86187 2742±125.8*** 5682±76.3*** 8421.26537.9
H1 receptor specific density in the hypothalamus of female Sprague Dawley rats following 5 weeks treatment with Olz, OlzEt, OlzHomo (3 mg/kg or 6 mg/kg), or vehicle
(Control). D2, and 5HT2A receptor specific densities in the striatum and prefrontal cortex of male Sprague Dawley rats, respectively, following 2 weeks pre-treatment with
Olz, OlzEt, OlzHomo (3 mg/kg), or vehicle (Control) and subcutaneous injection of Saline or PCP. Data are expressed as CPM: counts per minute; mean 6 SEM,
**P,0.01, and.
***P,0.001 vs. Control.
doi:10.1371/journal.pone.0080979.t002
Table 3. Open field test in male rats treated with Olz and Olz derivatives.
Open field test Control Olz OlzEt OlzHomo
Saline
Total distance moved (%)a 135.5636.6 110.2631.9 143.1649.1 118.7633.1
Mean velocity (cm/s) 20.263.7 18.263.3 14.061.0 16.961.8
Rearing frequency (%)a 118.6619.5 109.4630.5 122.7623.1 116.9622.1
Centre duration (s) 40.68610.1 40.3466.4 51.52693 86.16628.9
Periphery duration 1820.5617.5 1827.8628.3 1792.0616.2 1818.3614.6
Centre frequency 22.262.7 18.562.5 23.662.8 23.763.6
Periphery frequency (%)a 106.5628.9 133.0639.0 132.5620.8 118.3663.4
PCP
Total distance moved (%)a 357.6633.5## 217.9639.6* # 198.1628.9** 280.8626.6###
Mean velocity (cm/s) 22.061.5# 11.762.1*# 15.162.9 26.462.4#
Rearing frequency (%)a 209.6640.0 233.3671.0 258.6669.6 176.8629.8
Centre duration (s) 101.2619.5## 234.4662.9# 281.0636.11** ### 127.6638.4
Periphery duration 1770.5624.8 1666.6693.6 1585.4648.7* ### 1768.0636.7
Centre frequency 47.164.9### 36.566.1# 54.369.2### 45611.8
Periphery frequency (%)a 245.6624## 285.9699.6 376.4654.8## 238.7653.3
Open field testing in male Sprague Dawley rats following 2 weeks treatment with Olz, OlzEt , OlzHomo (3 mg/kg), or vehicle (Control). Data are expressed as mean 6
SEM,
*P,0.05 and.
**P,0.01 vs. Control.
#P,0.05,
##P,0.01, and.
###P,0.001 vs. Saline.
aNormalised data.
doi:10.1371/journal.pone.0080979.t003
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Prevention of weight gain and adiposity following OlzEt
and OlzHomo regimes
In contrast with study 2, female rats were used in study 1 since
the metabolic side effects following antipsychotic treatment (such
as Olz) reported in the literature have been more pronounced in
females compared to males [72]. The switch of gender for this
study should not influence the results since the most appropriate
animal model was chosen to be able to validate the different
hypothesis in the two respective studies. Similar to previous animal
studies [28] and clinical reports [29], our study showed that
chronic treatment with Olz (at both 3 and 6 mg/kg doses) induced
an increase in body weight gain, with higher doses causing a
greater effect. In contrast OlzEt, and particularly OlzHomo,
prevented weight gain over the treatment period. Our study also
confirmed previous findings in relation to hyperphagia and
enhanced energy efficiency induced by Olz treatment
[30,31,32]. Notably, food intake was increased in animals treated
with 6 mg/kg of Olz, indicating that energy consumption
contributed significantly to body weight gain in this group of
animals. On the other hand, food intake was not significantly
increased in the 3 mg/kg Olz-treated rats, despite a significant
increase in the body weight of these animals. These results suggest
that a decrease in energy expenditure may be associated with the
Olz-induced weight gain with the 3 mg/kg dose [33]. Coinciding
with previous studies [32,34], our findings report a positive
correlation between body weight gain and visceral fat deposition
despite Olz, OlzEt and OlzHomo inducing low visceral fat
deposition. Both peripheral and central factors may be involved in
Olz-induced weight gain and adiposity, nevertheless the exact
mechanisms by which this drug causes metabolic adverse side
effects still remains elusive [33]. The fat deposition may be
associated with the increase in body weight or be due to the direct
effects of Olz on adipose tissue [35,36]. Studies reporting Olz-
mediated peripheral adipogenesis in the 3T3-L1 cell model
showed an over-expression of fatty acid synthase and adiponectin
genes [37]. In accordance with this in vitro adipogenesis result and
with previous animal and clinical studies [34,38], our findings
support the effect of Olz administration on increasing plasma
adiponectin levels. However, our data may appear counterintu-
itive given that other studies reported a reduction of adiponectin in
obesity [39,40]. The correlation between plasma leptin levels and
visceral adiposity found in this study suggested that leptin may be a
useful indicator of fat mass deposition induced by Olz. Interest-
ingly, we found plasma leptin levels in animals treated with
OlzHomo were significantly reduced, which may confirm the
preventative effect of OlzHomo on visceral adiposity. A similar
outcome was found in the leptin levels of female rats treated with
ziprasidone, which has a low effect on weight gain and fat
deposition [41]. Numerous studies have shown that Olz-induced
weight gain is associated with elevated leptin levels in schizophre-
nia patients [42,43,44,45]. Since we have observed a link between
enhanced adiposity and leptin levels, the lack of a significant effect
of Olz treatment on leptin levels in our study may appear
surprising. However, our treatment duration was subchronic (5
weeks), which can explain the discrepancy of our data with chronic
studies performed with schizophrenia patients [42,43,44,45]. Our
study also showed a marked reduction in insulin secretion in the
6 mg/kg Olz treatment group with no significant change in the
3 mg/kg Olz, OlzEt, and OlzHomo-treated animals as illustrated
in Figure 3. These results support some recent findings that short
term treatment with Olz decreased insulin levels in rats and
schizophrenia patients [28,46]. On the other hand, an extensive
amount of literature has reported increased insulin levels following
chronic treatment with Olz, particularly in patients who gained a
significant amount of weight [47,48,49,50]. However, as a result of
increasing weight gain, chronic administration of Olz can lead to
compensatory hyperinsulinemia and insulin resistance, which are
commonly observed in clinical cases. The direct antagonistic effect
of Olz delivered at a high dose (6 mg/kg in rats represents around
double the dose for treatment in humans) on the muscarinic M3
receptors in the pancreatic b-cells which regulate insulin secretion
may contribute to the reduction in plasma insulin concentrations
observed in our study [52].
With regards to the levels of plasma glucose, our results did not
show any significant difference between the different treatment
groups (Olz, OlzEt and OlzHomo) compared to the controls,
which is in accordance with results from recent clinical studies
[71]. Since blood glucose levels depend not only on insulin
secretion, but also on tissue insulin utilisation, our results suggest
that there is no insulin resistance at the early stage of olanzapine
treatment in our study. Although weight gain was significant in
rats treated with Olz vs. vehicle rats, these animals seemed to
remain insulin sensitive. This is supported by our results showing
no significant difference in the lipid profiles performed in the Olz
treated rats compared to the vehicle rats.
The affinities of atypical antipsychotics for the 5HT2A, 5HT2C,
5HT6, a1A and H1 receptors and their obesogenic effects has been
repeatedly reported in various studies [2,15,16,17]. Particular
emphasis was placed on the ability of antipsychotics to block the
H1 receptors [19,20]. The blockade of the H1 receptors is directly
involved in the activation of the hypothalamic AMPK signalling
pathway, which stimulates food intake and positive energy balance
Table 4. Plasma lipid and glucose profiles in female rats treated with Olz and Olz derivatives.
Control Olz OlzEt OlzHomo
3 mg 6 mg 3 mg 6 mg 3 mg 6 mg
Cholesterol (mmol/L) 1.9860.22 1.5060.09 1.8160.08 1.6360.08 1.6360.06 1.7560.07 1.5060.06
Triglycerides (mmol/L) 1.1260.13 0.8560.12 1.1160.13 0.8960.12 0.8360.13 0.9060.08 0.8860.07
HDL (mmol/L) 0.1860.01 0.1460.02 0.1660.02 0.1260.01 0.1760.02* 0.2060.03** 0.1360.01
Cholesterol/HDL ratio (mmol/L) 11.5561.26 12.0361.58 12.0861.36 13.3060.68 10.8161.61 10.5061.37 12.8161.32
LDL (mmol/L) 1.3060.18 0.9860.09 1.1460.06 1.0960.08 1.0960.02 1.1460.07 0.8660.12
Mean concentrations of plasma lipids and glucose in female Sprague Dawley rats following 5 weeks treatment with Olz, OlzEt, OlzHomo (3 mg/kg or 6 mg/kg), or
vehicle (Control). Data are expressed as mean 6 SEM,
*P,0.05, and.
**P,0.01 vs. Control.
doi:10.1371/journal.pone.0080979.t004
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and reverses the anorexigenic effect of leptin [18]. This study
supports the potential role of H1 receptor affinity in antipsychotic-
induced weight gain and fat deposition. As shown in our previous
report [27], OlzEt and OlzHomo have a lower affinity for binding
to the H1 receptors (Ki = 1.95, and Ki = 13.63, respectively)
compared to that of Olz (Ki = 0.13). Therefore, the pronouced
antagonism of OlzEt and OlzHomo at the H1 receptors may be
responsible for their significantly attenuated propensity to induce
weight gain and metabolic dysfunction, which are associated with
Olz treatment. Furthermore, corresponding with previous reports,
the present study demonstrated a significant negative correlation
between hypothalamic H1 receptor density and weight gain and
accumulative fat mass in rats. H1 receptor density in the
hypothalamus has been markedly reduced following chronic
treatment with Olz (at both 3 mg/kg and 6 mg/kg doses) but
not with OlzEt and OlzHomo, supporting the importance of the
H1 receptor in Olz-induced obesogenic side effects. In agreement
with our observation, the down-regulation of H1 receptor
expression has been previously reported in the hypothalamic
nuclei of rats treated with Olz [33]. In addition, the nonsignificant
alterations of the H1 receptor density following OlzEt and
OlzHomo treatments may explain the lack of orexigenic effects
of these two compounds in the treated rats. Thus, the involvement
of the H1 receptors in Olz-induced obesity and fat deposition
might be closely related.
In general, while our study confirmed the effect of Olz
administration on metabolic alterations in rats, we showed that
OlzEt and OlzHomo administrations did not induce either
enhancing effects on body weight and food intake or detrimental
consequences on fat deposition and metabolism. Our findings
appear to have reasonable predictive validity for different aspects
of Olz-induced weight gain/adiposity and metabolic abnormalities
which mimic the clinical situation.
In conclusion, our findings confirmed the obesogenic effect of
Olz administration, coupled with the down-regulation of the H1
receptors in the hypothalamus. Our results showed that both
OlzEt and OlzHomo appear to be promising new candidate
compounds which did not result in weight gain, visceral fat
deposition and metabolic dysfunction. However, based on the
pharmacological proprieties alone, OlzEt presented with a similar
profile to Olz during behavioural assessment in the open-field test
with regards to blocking PCP-induced hyperactivities. These
findings suggest that the long lasting down-regulation of D2 and 5-
HT2A receptors induced by sub-chronic Olz and OlzEt treatment
may play a part in blocking PCP-induced behaviours. The fact
that OlzHomo had a reduced capacity to inhibit PCP-induced
behaviours could also be explained by its lower affinity for the D2
and 5HT2A receptors in the brain compared to that of Olz and
OlzEt. Therefore, if the OlzHomo regime was to be delivered at a
higher dose than that of Olz and OlzEt, then the therapeutic
effectiveness of OlzHomo may be increased. Given the limitations
associated with animal models, we suggest that the present results
be taken with caution. Only further behavioural studies and
clinical trials will reveal the predictive validity of this preclinical
model for the therapeutic efficacy and metabolic side effects of
these two compounds.
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